Zhengping Li, Medical Doctor in progress

M.D. in progress
zhengp_li@163.com
Beijing, Beijing, China (People's Republic)

Zhengping Li, M.D. in progress, Pediatric Hematology Physician, Comprehensive Treatment Team for Hemophilia, Beijing Children's Hospital Affiliated to Capital Medical University, National Children's Medical Center
Main research direction: children with coagulation disorders, mainly engaged in hemophilia profession. Specifically for immune tolerance induction in severe hemophilia A children with high titer inhibitors in countries with economic constraints.

Presentation(s):

• PB0506 - Influence of F8 gene mutation on outcome in immune tolerance induction of hemophilia A children with inhibitors

  Monday, June 24, 2024
  13:45 – 14:45 ICT

• PB0613 - Real-World Use of Emicizumab in Chinese Children with Hemophilia A: Retrospective Data from a Comprehensive Care Center

  Monday, June 24, 2024
  13:45 – 14:45 ICT

• PB0542 - Recommendation model to automatically assign immunosuppressants to low-dose immune tolerance induction individually in severe hemophilia A patients with inhibitors via causal inference

  Monday, June 24, 2024
  13:45 – 14:45 ICT

• PB0546 - The lower double negative T cells proportion predicted the better high-titer inhibitors eradication outcomes of immune tolerance induction

  Monday, June 24, 2024
  13:45 – 14:45 ICT

• OC 61.3 - More cost-effective of intermediate-dose immune tolerance induction regimen for severe hemophilia A children with high-titer inhibitors: the interim report of a randomized multicenter clinical trial

  Tuesday, June 25, 2024
  15:15 – 15:30 ICT